IMU.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:10):

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia...

Stats
Dzisiejszy wolumen	17.07M
Średni wolumen	15.87M
Kapitalizacja rynkowa	578.26M
EPS	$0 ( 2024-03-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.90
ATR14	$0 (0.00%)

Wolumen Korelacja

Długi: -0.12 (neutral)

Krótki: -0.69 (moderate negative)

Signal:(45.931) Neutral

Imugene Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Imugene Ltd Korelacja - Waluta/Towar

0.00
( neutral )

Imugene Ltd Finanse

Annual	2023
Przychody:	$11.78M
Zysk brutto:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2023
Przychody:	$11.78M
Zysk brutto:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2022
Przychody:	$12.97M
Zysk brutto:	$10.56M (81.44 %)
EPS:	$-0.00670

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.00453

Financial Reports:

No articles found.

Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.